Kiewit, which contracted to complete Phase 1 of the Key Bridge rebuild, will not be retained for Phase 2, Maryland and ...
Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to ...
The funding goal of $41 million for the first phase of an expansion of oncology services at Mercy Fort Smith has been reached ...
The firm contracted to complete Phase 1 of the Key Bridge rebuild will not be retained for Phase 2, state and federal ...
PLYMOUTH, Mass.--(BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing precision therapeutics for the treatment of cancers with ...
BOSTON--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing transformative bifunctional therapies for patients with solid tumors, today announced the presentation ...
CMMC Phase 1 officially began on November 10, 2025, but many defense contractors are still unsure if they’re fully ready for it. The confusion is understandable considering the years of delays and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results